WO2009143719A1 - Herbal extracts which induce immune cells to produce interferon and activate toll-like receptors - Google Patents

Herbal extracts which induce immune cells to produce interferon and activate toll-like receptors Download PDF

Info

Publication number
WO2009143719A1
WO2009143719A1 PCT/CN2009/070570 CN2009070570W WO2009143719A1 WO 2009143719 A1 WO2009143719 A1 WO 2009143719A1 CN 2009070570 W CN2009070570 W CN 2009070570W WO 2009143719 A1 WO2009143719 A1 WO 2009143719A1
Authority
WO
WIPO (PCT)
Prior art keywords
radix
herbal extract
receptors
toll
preparing
Prior art date
Application number
PCT/CN2009/070570
Other languages
French (fr)
Inventor
I Horng Pan
Lain-Tze Lee
Chih-Lung Chen
Hsin-Jan Yao
Chu-Hsun Lu
Chen Hsuan Lin
Ya-Yan Yang
Hsin-Hsin Shen
Ming-Feng Chen
Original Assignee
Industrial Technology Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/164,958 external-priority patent/US20090280200A1/en
Application filed by Industrial Technology Research Institute filed Critical Industrial Technology Research Institute
Publication of WO2009143719A1 publication Critical patent/WO2009143719A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/233—Bupleurum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
    • A61K31/79—Polymers of vinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/539—Scutellaria (skullcap)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Definitions

  • the invention relates to an herbal extract, and in particular relates to an herbal extract which induces immune cells to produce interferon and activates Toll-like receptors and a preparation method thereof.
  • Interferon the first cytokine discovered, which was capable of interfering with virus replication, was identified by British virologist Alick Isaacs and the Swiss researcher Jean Lindenmann in 1957. When cells are infected by viruses, interferon is immediately produced to fight against the virus infection and simultaneously warn neighboring normal cells to prevent virus invasion. Interferon is divided into two groups. Type I interferon comprises interferon- ⁇ , interferon- ⁇ , interferon- ⁇ and interferon- ⁇ and type II interferon comprises interferon- ⁇ . Interferon- ⁇ and interferon- ⁇ are produced in most cells. Interferon- ⁇ , however, is merely produced in a part of some immune cells, for example, natural killer cells, CD4 + T helper 1 (T H I) lymphocytes and CD8 + cytotoxic T lymphocytes.
  • T H I T helper 1
  • type I interferon is rapidly produced and binds to type I interferon receptors to start a JAK-STAT signal transduction pathway to open a interferon-stimulated gene (ISG) expression.
  • An interferon-stimulated protein is the best weapon of interferon, to fight against virus infection.
  • interferon-stimulated proteins have been identified, widely participating in, for example, anti-virus, apoptosis, protein degradation, inflammatory cell response and lipid metabolism.
  • Common interferon-stimulated proteins comprise protein kinase R (PKR), adenosine deaminase acting on RNA (ADAR), 2',5'-oligo adenylate synthetase (OAS), RNase L and Mx protein.
  • PPKR protein kinase R
  • ADAR adenosine deaminase acting on RNA
  • OF 2',5'-oligo adenylate synthetase
  • RNase L RNase L
  • Mx protein protein kinase R
  • PKR protein kinase R
  • ADAR adenosine deaminase acting on RNA
  • OF 2',5'-oligo adenylate synthetase
  • Mx protein inhibits virus replication.
  • type I interferon In addition to fighting against virus infection, type I interferon participates in immunomodulatory treatment, taking an important role in innate immune response and adaptive immune response. Type I interferon induces immune cells to produce IL- 15 to promote survival and proliferation of natural killer cells and simultaneously stimulates MHC, CD80, CD86 and CD40 molecules to mature dendritic cells. Additionally, type I interferon induces differentiation of plasmacytoid dendritic cells (pDC) to form mature antigen presenting cells. In adaptive immune response, type I interferon plays an important role in activity of CD8 + cytotoxic T lymphocytes, survival of CD4 + T helper 1 (T H I) lymphocytes and CD8 + cytotoxic T lymphocytes, and differentiation and proliferation of B lymphocytes.
  • T H I CD4 + T helper 1
  • Type I interferon has been successfully utilized in clinical therapy, benefiting anti-virus, cell growth regulation and immunomodulatory treatments.
  • beneficial clinical therapy treatments were seen for viral diseases such as chronic hepatitis B, chronic hepatitis C, condyloma and Kaposi's sarcoma, hematological diseases such as hairy cell leukemia, chronic myeloid leukemia, multiple myeloma and Non-Hodgkin's lymphoma, and other tumors such as melanoma, renal cell carcinoma and basal cell carcinoma.
  • TLR Toll-like receptors
  • Toll was found from fruit fly in 1988. Toll-like receptors were subsequently found from mammals.
  • PAMPs pathogen-associated molecular patterns
  • Toll-like receptors recognize pathogen-associated molecular patterns (PAMPs) thereof to open a downstream gene expression through a signal transduction pathway, for example, by formation of cytokine (type I interferon, IL-I, IL-12 and interferon- ⁇ ), chemotactic substance, MHC and co-stimulatory molecules.
  • Toll-like receptors induce inducible nitric oxide synthase (iNOS) and antimicrobial peptide expression to start an innate immune response to directly damage the foreign pathogen.
  • iNOS inducible nitric oxide synthase
  • Toll-like receptors induce maturation of antigen presenting cells (dendritic cells) to activate adaptive immune response.
  • dendritic cells antigen presenting cells
  • Toll-like receptors of dendritic cells recognize pathogen and present pathogen's antigen on a cell surface through an MHC molecule.
  • Native T lymphocytes are then activated and differentiated to the Th 1 lymphocytes by stimulation of IL-12 produced by inducing dendritic cells by the Toll-like receptors to start the adaptive immune response against the chronic virus infection, providing powerful and specific immune protection.
  • Currently known Toll-like receptors comprise the Toll-like receptor 1 to Toll-like receptor 10, which are capable of recognizing various foreign substances, for example, bacteria, virus, fungus and protozoan.
  • a Toll-like receptor structure has two parts comprising an extracellular leucine-rich repeat (LRR) and an intracellular Toll-interleukin-1 receptor (TIR) domain.
  • the extracellular leucine-rich repeat (LRR) recognizes foreign substances.
  • the intracellular Toll-interleukin-1 receptor (TIR) domain combines with downstream adaptor proteins, for example, myeloid differentiation factor-88 (MyD88), TIR-associated protein (TIRAP/MAL), Toll/IL-1 receptor domain-containing adaptor inducing IFN- ⁇ (TRIF/TICAM-1) and Toll-receptor-associated molecule (TRAM/TIRP/TICAM-2), to activate the extracellular signal-regulated kinase (ERK), p38, c-Jun N-terminal kinase and NF-kB to induce formation of pro-inflammatory cytokines such as IL-I, IL-6, interferon- ⁇ and type I interferon.
  • MyD88 myeloid differentiation factor-
  • the Toll-like receptor 4 which is expressed in many immune cells, for example, B lymphocytes, dendritic cells, monocytes, macrophages, granulocytes and T lymphocytes, is capable of recognizing various foreign viruses such as respiratory syncytial virus (RSV), hepatitis C virus (HCV) and mouse mammary tumor virus (MMTV), and induces immune cells to produce considerable quantities of interferon through combining with MyD88 and TIRAP.
  • RSV respiratory syncytial virus
  • HCV hepatitis C virus
  • MMTV mouse mammary tumor virus
  • the Toll-like 2 recognizes maximum PAMPs, for example, lipoarabinomannan (LAM), lipopolysaccharide (LPS), lipoteichoic acid (LTA), peptidoglycan (PGN) and other lipoproteins, glycolipids and glycoproteins, mostly deriving from bacteria.
  • LAM lipoarabinomannan
  • LPS lipopolysaccharide
  • LTA lipoteichoic acid
  • PPN peptidoglycan
  • virus invasion for example, the measles virus (MV), human cytomegalovirus (HCMV) and hepatitis C virus.
  • the Toll-like receptor 7 is highly expressed in monocytes, B lymphocytes and dendritic cells. Once foreign substance invasion is recognized, considerable quantities of type I interferon are produced, especially interferon- ⁇ , which plays an important role in innate immune response.
  • the Toll-like receptor 7 detects G/U-rich ssRNA, which is derived from viruses, for example, human immunodeficiency virus (HIV) and VSV.
  • Toll-like receptor 9 antagonist With the development of drugs, the Toll-like receptor 9 antagonist has entered clinical trials, which stimulates dendritic cells to produce IL-12 and considerable quantities of interferon- ⁇ and induces B lymphocyte proliferation and antibody secretion, with a good curative effect on HVC patients whom did not positively react to the conventional interferon- ⁇ treatment. Toll-like receptor 9 antagonist induces cells to exhibit a wide antiviral response and release various cytokines, especially interferon- ⁇ , achieving a high virus scavenging efficiency on various HVC genotype patients.
  • antiviral drugs have been developed and widely applied in clinical therapy, for example, ribavirin, a nucloside analog, inhibiting growth of various viruses such as respiratory syncytial virus, influenza virus, adenovirs, HIV and HCV, amantadine, inhibiting M2 membrane proteins of influenza virus A to block virus replication, and zidovudine (AZT) , didanosine (ddl) , zalcitabine (ddc) , stavudine (d4T) and lamivudine
  • viruses such as respiratory syncytial virus, influenza virus, adenovirs, HIV and HCV
  • amantadine inhibiting M2 membrane proteins of influenza virus A to block virus replication
  • zidovudine ZT
  • didanosine ddl
  • ddc didanosine
  • ddc zalcitabine
  • d4T stavudine
  • mutation of the thymidine kinase gene of the HSV results in blocking of the conversion from acyclovir and ganciclovir to effective substances in cells, thus forming drug resistance to such drugs.
  • mutation of the M2 membrane protein gene of influenza virus A results in formation of drug resistance to amantadine and rimantadine
  • mutation of the reverse transcriptase or protease gene of HIV results in formation of drug resistance
  • mutation of the non- structural 5 A, envelope gene and 2-glycoprotein gene of HCV results in formation of drug resistance to interferon.
  • immunity of normal organisms may be simultaneously improved.
  • 6,696,094 discloses a pharmaceutical composition containing aqueous extracts of fourteen (14) herbal ingredients including Hedyotis Diffuse and so on, with the form of an intravenous injection solution or capsules, exhibiting an anti-HIV effect in clinical trials.
  • US. Pat. 6,214,350 discloses an herbal prescription (HHT888-4) containing Flos Lonicerae, Glycyrrhizae Radix and Solarium Nigrum, which inhibited HIV activity to achieve over 98% in lymphocytes in vitro trials.
  • HHT888-4 Flos Lonicerae
  • Glycyrrhizae Radix and Solarium Nigrum
  • 6,426,098 discloses an herbal extract comprising Curcuma Longa, Astragalus Membranaceus, Loranthus Parasiticus and Polygonum Cuspidatum, which possessed a prominent curative effect on hepatitis C in clinical trials.
  • US. Pat. 2003/0211180 discloses an herbal composition (PHY906) comprising Ziziphus, which is utilized with chemotherapy drugs to increase curative effects on viral diseases, improve quality of life and reduce toxicity and negative side effects.
  • the herbal composition has already entered the phase-II clinical trials in the U.S.. Taiwan Pat. 1258373 discloses utilization of a hepatitis C assisted drug comprising Cordyceps Sinensis and Astragalus Membranaceus, which is incorporated with a hepatitis C composite treatment (interferon and ribavirin) to achieve over 70% virus scavenging efficiency. In addition to curative effect, recurrence is reduced.
  • WO 02102395 discloses an antiviral effect of an herbal extract comprising Nerium Indicum Mill and Glycyrrhizae Radix on HEp-2 cells infected by encephalo-myocarditis virus (EMCV). EMCV is effectively inhibited. In vitro, interferon- ⁇ is also produced thereby.
  • TLRs Toll-like receptors
  • pathogens virus, bacteria or fungus
  • individual TLRs recognize pathogens and start corresponding immune responses. Binding between TLRs and pathogens are specific, inducing a series of reactions to protect cells from pathogen invasion.
  • TLR treatment due to a high specificity of TLR to immune response, stimulators (agonists) or blockers (antagonists) are specifically administrated to induce self-immunomodulatory to achieve curative effect. Due to the high specificity of the treatment, in addition to continuous inhibition of pathogens, side effects and disorders resulting from non-specific activation of the innate immune system are reduced.
  • Actilon (a TLR drug), a synthetic short-chain oligonucleotides (ODNs) compound, has been developed by the Coley Pharmaceutical Group.
  • the short-chain ODNs compound is similar to the DNA sequence, with a CpG structure of pathogen recognizable by TLR-9.
  • interferon is produced to treat a viral disease, for example, hepatitis C.
  • Actilon has entered phase-Ib clinical trials.
  • ANA245 and ANA975 oral form developed by Anadys Pharmaceutical Corporation is utilized to induce TLR-7 presentation. They have respectively entered phase-Ib and phase-la clinical trials.
  • herbal extracts can be utilized in TLR treatments.
  • WO 04093518 discloses a melanin extract oi Echinacea, which was tested in monocyte (NF-kappa B/luciferase) in vitro. The melanin extract induced presentation of TLR-2 and TLR-4.
  • One embodiment of the invention provides an herbal extract which induces immune cells to produce interferon and activates Toll-like receptors, extracted from an effective amount of raw material comprising Glycyrrhizae Radix, Bupleuri Radix and Scutellariae Radix, wherein
  • Glycyrrhizae Radix, Bupleuri Radix and Scutellariae Radix have a weight ratio of 1-5: 1-5: 1-5 or 1-2: 1-2: 1-2.
  • Glycyrrhizae Radix comprises Glycyrrhiza uralensis or Glycyrrhiza glabra.
  • Bupleuri Radix comprises Bupleurum chinense or Bupleurum scorzonerifolium.
  • Scutellariae Radix comprises Scutellaria baicalensis.
  • the raw material of the herbal extract further comprises an effective amount of Schisandrae Fructus and Paeoniae Rubra Radix.
  • Glycyrrhizae Radix, Bupleuri Radix, Scutellariae Radix, Schisandrae Fructus and Paeoniae Rubra Radix have a weight ratio of 1-5: 1-5: 1-5: 1-3: 1-3 or 1-2: 1-2: 1-2: 1-2: 1-2.
  • Schisandrae Fructus comprises Schisandra chinensis or Schisandra sphenanthera.
  • Paeoniae Rubra Radix comprises Paeonia lacti flora or Paeonia veitchii.
  • the herbal extract activates various Toll-like receptors, for example, Toll-like receptor 2, Toll-like receptor 4 and Toll-like receptor 7.
  • the herbal extract strengthens immune regulation, suitable for use in treatment of viral infectious diseases.
  • One embodiment of the invention provides a method for preparing an herbal extract which induces immune cells to produce interferon and activates Toll-like receptors, comprising providing an herbal composition comprising an effective amount of Glycyrrhizae Radix, Bupleuri Radix and Scutellariae Radix, wherein Glycyrrhizae Radix, Bupleuri Radix and Scutellariae Radix have a weight ratio of 1-5: 1-5: 1-5 or 1-2: 1-2: 1-2, extracting the herbal composition with a solvent to form an extract solution, concentrating the extract solution to form a concentrated product, drying the concentrated product and adding an excipient to prepare a specific formulation.
  • Glycyrrhizae Radix comprises Glycyrrhiza uralensis or Glycyrrhiza glabra.
  • Bupleuri Radix comprises Bupleurum chinense or Bupleurum scorzonerifolium.
  • Scutellariae Radix comprises Scutellaria baicalensis.
  • the herbal composition further comprises an effective amount of Schisandrae Fructus and Paeoniae Rubra Radix.
  • Glycyrrhizae Radix, Bupleuri Radix, Scutellariae Radix, Schisandrae Fructus and Paeoniae Rubra Radix have a weight ratio of 1- 5: 1-5: 1-5: 1-3:1-3 or 1-2: 1-2: 1-2: 1-2: 1-2.
  • Schisandrae Fructus comprises Schisandra chinensis or Schisandra sphenanthera.
  • Paeoniae Rubra Radix comprises Paeonia lactiflora or Paeonia veitchii.
  • the solvent comprises water or 0.1-95% ethanol.
  • the solvent and the herbal composition have a weight ratio of 6: 1-10: 1.
  • the concentrated product has a solid content of 10-30%.
  • the concentrated product is dried by vacuum drying, freeze drying, spray drying or fluidized bed drying.
  • the excipient comprises starch, maltose, lactose, sucrose, mannitol, magnesium stearate, silicon dioxide, microcrystalline cellulose, carboxymethyl cellulose or talc powder.
  • the specific formulation comprises capsule, tablet, powder or fluid.
  • FIG. IA shows cell toxicity of the herbal extract in neutrophil according to an embodiment of the invention.
  • FIG. IB shows cell toxicity of the herbal extract in T lymphocytes according to an embodiment of the invention.
  • FIG. 2A shows quantity of interferon- ⁇ produced by inducing natural killer cells and T lymphocytes by the herbal extract according to an embodiment of the invention.
  • FIG. 2B shows quantity of interferon- ⁇ produced by inducing natural killer cells by the herbal extract according to an embodiment of the invention.
  • FIG. 2C shows quantity of interferon- ⁇ produced by inducing T lymphocytes by the herbal extract according to an embodiment of the invention.
  • FIG. 3 shows quantity of interferon- ⁇ induced by the herbal extract in a subject according to an embodiment of the invention.
  • FIGS. 4A-4I show expressions of Toll-like receptors of PBMC/T cells activated by the herbal extract according to an embodiment of the invention.
  • FIGS. 5A-5I show expressions of Toll-like receptors of PBMC/T cells activated by the herbal extract according to an embodiment of the invention.
  • FIGS. 6A-6I show expressions of Toll-like receptors of PBMC/T cells activated by the herbal extract according to an embodiment of the invention.
  • FIGS. 7A-7I show expressions of Toll-like receptors of PBMC/T cells activated by the herbal extract according to an embodiment of the invention.
  • FIGS. 8A-8I show expressions of Toll-like receptors of PBMC/T cells activated by the herbal extract according to an embodiment of the invention.
  • FIGS. 9A-9I show expressions of Toll-like receptors of PBMC/T cells activated by the herbal extract according to an embodiment of the invention.
  • FIGS. 10A- 101 show expressions of Toll-like receptors of PBMC/T cells activated by the herbal extract according to an embodiment of the invention.
  • FIGS. 1 IA-I II show expressions of Toll-like receptors of PBMC/T cells activated by the herbal extract according to an embodiment of the invention.
  • One embodiment of the invention provides an herbal extract which induces immune cells to produce interferon and activates Toll-like receptors, extracted from an effective amount of raw material comprising Glycyrrhizae Radix, Bupleuri Radix and Scutellariae Radix.
  • Glycyrrhizae Radix, Bupleuri Radix and Scutellariae Radix have a weight ratio of about 1-5: 1-5: 1-5 or 1-2: 1-2: 1-2.
  • Glycyrrhizae Radix may comprise Glycyrrhiza uralensis or Glycyrrhiza glabra.
  • Bupleuri Radix may comprise Bupleurum chinense or Bupleurum scorzonerifolium.
  • Scutellariae Radix may comprise Scutellaria baicalensis.
  • the raw material of the herbal extract may further comprise an effective amount of Schisandrae Fructus and Paeoniae Rubra Radix.
  • Glycyrrhizae Radix, Bupleuri Radix, Scutellariae Radix, Schisandrae Fructus and Paeoniae Rubra Radix have a weight ratio of about 1-5: 1-5: 1-5: 1-3: 1-3 or 1-2:1-2: 1-2: 1-2: 1-2.
  • Schisandrae Fructus may comprise Schisandra chinensis or Schisandra sphenanthera.
  • Paeoniae Rubra Radix may comprise Paeonia lactiflora or Paeonia veitchii.
  • the herbal extract activates various Toll-like receptors, for example, Toll-like receptor 2, Toll-like receptor 4 and Toll-like receptor 7.
  • One embodiment of the invention provides a method for preparing an herbal extract which induces immune cells to produce interferon and activates Toll-like receptors, comprising the following steps.
  • An herbal composition comprising an effective amount of Glycyrrhizae Radix, Bupleuri Radix and Scutellariae Radix is provided. Glycyrrhizae Radix, Bupleuri Radix and Scutellariae Radix have a weight ratio of about 1-5: 1-5: 1-5 or 1-2: 1-2: 1-2.
  • the herbal composition is then extracted with a solvent to form an extract solution. Next, the extract solution is concentrated to form a concentrated product. The concentrated product is then dried. Next, an excipient is added to prepare a specific formulation.
  • Glycyrrhizae Radix may comprise Glycyrrhiza uralensis or Glycyrrhiza glabra.
  • Bupleuri Radix may comprise Bupleurum chinense or Bupleurum scorzonerifolium.
  • Scutellariae Radix may comprise Scutellaria baicalensis.
  • the herbal composition may further comprise an effective amount of Schisandrae Fructus and Paeoniae Rubra Radix.
  • Glycyrrhizae Radix, Bupleuri Radix, Scutellariae Radix, Schisandrae Fructus and Paeoniae Rubra Radix have a weight ratio of about 1-5: 1-5: 1-5: 1-3: 1-3 or 1-2: 1-2: 1-2: 1-2: 1-2.
  • Schisandrae Fructus may comprise Schisandra chinensis or Schisandra sphenanthera.
  • Paeoniae Rubra Radix may comprise Paeonia lactiflora or Paeonia veitchii.
  • the solvent may comprise water or 0.1-95% ethanol.
  • the solvent and the herbal composition have a weight ratio of about 6: 1-10: 1.
  • the concentrated product has a solid content of about 10-30%.
  • the concentrated product is dried by, for example, vacuum drying, freeze drying, spray drying or fluidized bed drying.
  • the excipient may comprise starch, maltose, lactose, sucrose, mannitol, magnesium stearate, silicon dioxide, microcrystalline cellulose, carboxymethyl cellulose or talc powder.
  • the specific formulation may comprise capsule, tablet, powder or fluid.
  • a raw material comprising Glycyrrhizae Radix, Bupleuri Radix, Scutellariae Radix,
  • Schisandrae Fructus and Paeoniae Rubra Radix with a specific weight ratio is provided.
  • the raw material is then extracted with 0.1-95% ethanol one or more times to form an extract solution.
  • the weight of the ethanol is 6-fold to 10-fold times the raw material.
  • the extract solution is concentrated to form a concentrated product with a solid content of 10-30%.
  • the dried herbal extract powders are then filled in a hard capsule. Each capsule is filled with about 1.35 ⁇ 0.09g of the herbal extracts.
  • the herbal extract is concentrated to 2-fold to 3 -fold times the original content.
  • interferon production and Toll-like receptor expression for example, Toll-like receptor 2, Toll-like receptor 4 and Toll-like receptor 7 expressions, in neutrophil, T lymphocytes and natural killer cells are observed.
  • the results act as a drug screening basis.
  • Glycyrrhiza uralensis 4kg Paeonia lactiflora, 4kg Schisandra chinensis (a weight ratio of 1 : 1 : 1 : 1 : 1) and 200kg ethanol (30%) was thermal-extracted with reflux for one hour. After two extractions, an extract solution was formed and filtered through a lOOmesh. After reduced pressure concentration, a concentrated product with a 15% solid content was formed. 2kg dextrin-maltose was then added and the product was freeze-dried to form a dried product. Next, the dried product was grounded to form powders with a diameter of less than 35mesh and then the product was blended with 12Og silicon dioxide and 6Og magnesium stearate. The dried herbal extract powders were then filled in a 0# hard capsule. The filling amount of each capsule was 565 ⁇ 40mg, approximately 1.35 ⁇ 0.09g of herbal extracts.
  • Glycyrrhiza uralensis 7.5g Paeonia lacti flora, 7.5g Schisandra chinensis (a weight ratio of 1 : 1 : 1 :3:3) and 25Og ethanol (30%) was thermal-extracted with reflux for one hour. After two extractions, an extract solution was formed and filtered through a lOOmesh. After reduced pressure concentration and freeze-drying, a dried product was grounded to form powders.
  • Glycyrrhiza uralensis (a weight ratio of 2: 1 : 1) and 25Og ethanol (30%) was thermal-extracted with reflux for one hour. After two extractions, an extract solution was formed and filtered through a lOOmesh. After reduced pressure concentration and freeze-drying, a dried product was grounded to form powders.
  • a solution containing 6.25g Scutellaria baicalensis, 12.5g Bupleurum chinense, 6.25g Glycyrrhiza uralensis (a weight ratio of 1 :2: 1) and 25Og ethanol (30%) was thermal-extracted with reflux for one hour. After two extractions, an extract solution was formed and filtered through a lOOmesh. After reduced pressure concentration and freeze-drying, a dried product was grounded to form powders.
  • Example 5 A solution containing 6.25g Scutellaria baicalensis, 6.25g Bupleurum chinense, 12.5g
  • a solution containing 5g Scutellaria baicalensis, 5g Bupleurum chinense, 5g Glycyrrhiza uralensis, 5g Paeonia lactiflora, 5g Schisandra chinensis (a weight ratio of 1 : 1 : 1 : 1 : 1) and 25Og water was thermal-extracted with reflux for one hour. After two extractions, an extract solution was formed and filtered through a lOOmesh. After reduced pressure concentration and freeze-drying, a dried product was grounded to form powders.
  • a solution containing 5g Scutellaria baicalensis, 5g Bupleurum chinense, 5g Glycyrrhiza uralensis, 5g Paeonia lactiflora, 5g Schisandra chinensis (a weight ratio of 1 : 1 : 1 : 1 : 1) and 25Og ethanol (95%) was thermal-extracted with reflux for one hour. After two extractions, an extract solution was formed and filtered through a lOOmesh. After reduced pressure concentration and freeze-drying, a dried product was grounded to form powders.
  • T lymphocytes is non-obvious.
  • Example 10 The herbal extract (prepared by Example 1) was added in T lymphocytes and natural killer cells (NK92) separated from peripheral blood. After 24 hours, the upper-layered solution was collected and the quantity of interferon thereof was measured by ELISA. The results indicated that the quantity of interferon- ⁇ increased as the concentration of the herbal extract increased, exhibiting a dosage effect, as shown in FIG. 2A. The dosage effect appears in both the T lymphocytes and natural killer cells (NK92). The quantity of interferon- ⁇ induced by PC-IL- 12 (positive control) and the herbal extract was measured in the same manner.
  • Example 13 The inducing activity for interferon- ⁇ of the herbal extract (prepared by Example 5) was tested. The results indicated that the immune cells were induced by the sample with 500 ⁇ g/mL to produce interferon- ⁇ of 129.1+8.5pg/mL (the immune cells were induced by IL- 12 (positive control) with 40ng/mL to produce interferon- ⁇ of 50+2.04pg/mL).
  • Example 13 The inducing activity for interferon- ⁇ of the herbal extract (prepared by Example 5) was tested. The results indicated that the immune cells were induced by the sample with 500 ⁇ g/mL to produce interferon- ⁇ of 129.1+8.5pg/mL (the immune cells were induced by IL- 12 (positive control) with 40ng/mL to produce interferon- ⁇ of 50+2.04pg/mL).
  • Example 14 The inducing activity for interferon- ⁇ of the herbal extract (prepared by Example 6) was tested. The results indicated that the immune cells were induced by the sample with l,000 ⁇ g/mL to produce interferon- ⁇ of 95.2+15.7pg/mL (the immune cells were induced by IL-12 (positive control) with 40ng/mL to produce interferon- ⁇ of 50+2.04pg/mL).
  • Example 14 The inducing activity for interferon- ⁇ of the herbal extract (prepared by Example 6) was tested. The results indicated that the immune cells were induced by the sample with l,000 ⁇ g/mL to produce interferon- ⁇ of 95.2+15.7pg/mL (the immune cells were induced by IL-12 (positive control) with 40ng/mL to produce interferon- ⁇ of 50+2.04pg/mL).
  • Example 15 The inducing activity for interferon- ⁇ of the herbal extract (prepared by Example 7) was tested. The results indicated that the immune cells were induced by the sample with l,000 ⁇ g/mL to produce interferon- ⁇ of l,563.6+44.9pg/mL (the immune cells were induced by IL-12 (positive control) with 40ng/mL to produce interferon- ⁇ of 50+2.04pg/mL).
  • the inducing activity for interferon- ⁇ of the herbal extract was tested.
  • the inducing activity for interferon- ⁇ in a living animal of the herbal extract was tested. After feeding (28 days), the quantity of interferon- ⁇ in blood of Wistar rats (control: drinking water; medium: feeding the herbal extract of 5g/kg; high: feeding the herbal extract of 10g/kg) was measured on the 29 th day. The results indicated that the quantity of interferon- ⁇ induced by the herbal extract in a subject was obvious, especially in female rats, as shown in FIG. 3. Test of expression of Toll-like receptors of PBMC/T cells activated by the herbal extract
  • TLR2 Toll-like receptor 2
  • TLR4 Toll-like receptor 4
  • TLR7 Toll-like receptor 7
  • Example 18 The expressions of Toll-like receptor 2 (TLR2), Toll-like receptor 4 (TLR4) and Toll- like receptor 7 (TLR7) activated by the herbal extract (prepared by Example 2) were tested. The results are shown in FIGS. 5A-5I. When the herbal extract of 500 ⁇ g/mL was applied, expressions of above 65% for the TLR2, TLR4 and TLR7 were achieved.
  • TLR2 Toll-like receptor 2
  • TLR4 Toll-like receptor 4
  • TLR7 Toll-like receptor 7
  • Example 19 The expressions of Toll-like receptor 2 (TLR2), Toll-like receptor 4 (TLR4) and Toll- like receptor 7 (TLR7) activated by the herbal extract (prepared by Example 3) were tested. The results are shown in FIGS. 6A-6I. When a low dosage (250 ⁇ g/mL) of the herbal extract was applied, expressions of above 60% for the TLR2, TLR4 and TLR7 were achieved.
  • TLR2 Toll-like receptor 2
  • TLR4 Toll-like receptor 4
  • TLR7 Toll-like receptor 7
  • Example 20 The expressions of Toll-like receptor 2 (TLR2), Toll-like receptor 4 (TLR4) and Toll- like receptor 7 (TLR7) activated by the herbal extract (prepared by Example 4) were tested. The results are shown in FIGS. Ik-Il. When a low dosage (250 ⁇ g/mL) of the herbal extract was applied, expressions of above 85% for theTLR2, TLR4 and TLR7 were achieved.
  • TLR2 Toll-like receptor 2
  • TLR4 Toll-like receptor 4
  • TLR7 Toll-like receptor 7
  • Example 21 The expressions of Toll-like receptor 2 (TLR2), Toll-like receptor 4 (TLR4) and Toll- like receptor 7 (TLR7) activated by the herbal extract (prepared by Example 5) were tested. The results are shown in FIGS. 8A-8I. When a low dosage (250 ⁇ g/mL) of the herbal extract was applied, expressions of above 80% for the TLR2, TLR4 and TLR7 were achieved.
  • Example 22 The expressions of Toll-like receptor 2 (TLR2), Toll-like receptor 4 (TLR4) and Toll- like receptor 7 (TLR7) activated by the herbal extract (prepared by Example 6) were tested. The results are shown in FIGS. 9A-9I. When a low dosage (250 ⁇ g/mL) of the herbal extract was applied, expressions of above 85% for the TLR2, TLR4 and TLR7 were achieved.
  • TLR2 Toll-like receptor 2
  • TLR4 Toll-like receptor 4
  • TLR7 Toll-like receptor 7
  • TLR2 Toll-like receptor 2
  • TLR4 Toll-like receptor 4
  • TLR7 Toll-like receptor 7

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A herbal extract which induces immune cells to produce interferon and activates Toll-like receptors and a preparation method thereof are provided. The herbal extract is extracted from an effective amount of raw materials including Radix Glycyrrhizae, Radix Bupleuri, Radix Scutellariae, Fructus Schisandrae and Radix Paeoniae Rubra. Radix Glycyrrhizae, Radix Bupleuri, Radix Scutellariae, Fructus Schisandrae and Radix Paeoniae Rubra have a weight ratio of 1-5:1-5:1-5:1-3:1-3.

Description

HERBAL EXTRACTS WHICH INDUCE IMMUNE CELLS TO PRODUCE INTERFERON AND ACTIVATE TOLL-LIKE RECEPTORS
CROSS REFERENCE TO RELATED APPLICATIONS
This Application claims priority of Chinese Application No. 200810098712.6, filed on May 30, 2008, and US patent application 12/164,958, filed on June 30, 2008, the entirety of which are incorporated by reference herein.
BACKGROUND OF THE INVENTION
Field of the Invention
The invention relates to an herbal extract, and in particular relates to an herbal extract which induces immune cells to produce interferon and activates Toll-like receptors and a preparation method thereof.
Description of the Related Art
Interferon (IFN), the first cytokine discovered, which was capable of interfering with virus replication, was identified by British virologist Alick Isaacs and the Swiss researcher Jean Lindenmann in 1957. When cells are infected by viruses, interferon is immediately produced to fight against the virus infection and simultaneously warn neighboring normal cells to prevent virus invasion. Interferon is divided into two groups. Type I interferon comprises interferon-α, interferon-β, interferon-ω and interferon-τ and type II interferon comprises interferon-γ. Interferon-α and interferon-β are produced in most cells. Interferon-γ, however, is merely produced in a part of some immune cells, for example, natural killer cells, CD4+ T helper 1 (THI) lymphocytes and CD8+ cytotoxic T lymphocytes.
During virus infection, type I interferon is rapidly produced and binds to type I interferon receptors to start a JAK-STAT signal transduction pathway to open a interferon-stimulated gene (ISG) expression. An interferon-stimulated protein is the best weapon of interferon, to fight against virus infection. Currently, more than 500 interferon-stimulated proteins have been identified, widely participating in, for example, anti-virus, apoptosis, protein degradation, inflammatory cell response and lipid metabolism. Common interferon-stimulated proteins comprise protein kinase R (PKR), adenosine deaminase acting on RNA (ADAR), 2',5'-oligo adenylate synthetase (OAS), RNase L and Mx protein. PKR inhibits eukaryotic initiation factor 2 (eIF2) to block virus protein synthesis. ADAR inhibits RNA editing. OAS and RNase L collapse virus RNA. Mx protein inhibits virus replication.
In addition to fighting against virus infection, type I interferon participates in immunomodulatory treatment, taking an important role in innate immune response and adaptive immune response. Type I interferon induces immune cells to produce IL- 15 to promote survival and proliferation of natural killer cells and simultaneously stimulates MHC, CD80, CD86 and CD40 molecules to mature dendritic cells. Additionally, type I interferon induces differentiation of plasmacytoid dendritic cells (pDC) to form mature antigen presenting cells. In adaptive immune response, type I interferon plays an important role in activity of CD8+ cytotoxic T lymphocytes, survival of CD4+ T helper 1 (THI) lymphocytes and CD8+ cytotoxic T lymphocytes, and differentiation and proliferation of B lymphocytes.
Type I interferon has been successfully utilized in clinical therapy, benefiting anti-virus, cell growth regulation and immunomodulatory treatments. Examples of beneficial clinical therapy treatments were seen for viral diseases such as chronic hepatitis B, chronic hepatitis C, condyloma and Kaposi's sarcoma, hematological diseases such as hairy cell leukemia, chronic myeloid leukemia, multiple myeloma and Non-Hodgkin's lymphoma, and other tumors such as melanoma, renal cell carcinoma and basal cell carcinoma.
In accordance with current research, interferon is produced by activation of Toll-like receptors (TLR). Toll was found from fruit fly in 1988. Toll-like receptors were subsequently found from mammals. When a foreign pathogen invades an entity, Toll-like receptors recognize pathogen-associated molecular patterns (PAMPs) thereof to open a downstream gene expression through a signal transduction pathway, for example, by formation of cytokine (type I interferon, IL-I, IL-12 and interferon-α), chemotactic substance, MHC and co-stimulatory molecules. Toll-like receptors induce inducible nitric oxide synthase (iNOS) and antimicrobial peptide expression to start an innate immune response to directly damage the foreign pathogen. Furthermore, Toll-like receptors induce maturation of antigen presenting cells (dendritic cells) to activate adaptive immune response. When a microorganism invades an entity, Toll-like receptors of dendritic cells recognize pathogen and present pathogen's antigen on a cell surface through an MHC molecule. Native T lymphocytes are then activated and differentiated to the Th1 lymphocytes by stimulation of IL-12 produced by inducing dendritic cells by the Toll-like receptors to start the adaptive immune response against the chronic virus infection, providing powerful and specific immune protection. Currently known Toll-like receptors comprise the Toll-like receptor 1 to Toll-like receptor 10, which are capable of recognizing various foreign substances, for example, bacteria, virus, fungus and protozoan. A Toll-like receptor structure has two parts comprising an extracellular leucine-rich repeat (LRR) and an intracellular Toll-interleukin-1 receptor (TIR) domain. The extracellular leucine-rich repeat (LRR) recognizes foreign substances. The intracellular Toll-interleukin-1 receptor (TIR) domain combines with downstream adaptor proteins, for example, myeloid differentiation factor-88 (MyD88), TIR-associated protein (TIRAP/MAL), Toll/IL-1 receptor domain-containing adaptor inducing IFN- β (TRIF/TICAM-1) and Toll-receptor-associated molecule (TRAM/TIRP/TICAM-2), to activate the extracellular signal-regulated kinase (ERK), p38, c-Jun N-terminal kinase and NF-kB to induce formation of pro-inflammatory cytokines such as IL-I, IL-6, interferon-α and type I interferon.
In mammals, the Toll-like receptor 4, which is expressed in many immune cells, for example, B lymphocytes, dendritic cells, monocytes, macrophages, granulocytes and T lymphocytes, is capable of recognizing various foreign viruses such as respiratory syncytial virus (RSV), hepatitis C virus (HCV) and mouse mammary tumor virus (MMTV), and induces immune cells to produce considerable quantities of interferon through combining with MyD88 and TIRAP.
Among overall Toll-like receptors, the Toll-like 2 recognizes maximum PAMPs, for example, lipoarabinomannan (LAM), lipopolysaccharide (LPS), lipoteichoic acid (LTA), peptidoglycan (PGN) and other lipoproteins, glycolipids and glycoproteins, mostly deriving from bacteria. Also, the Toll-like receptor 2 recognizes virus invasion, for example, the measles virus (MV), human cytomegalovirus (HCMV) and hepatitis C virus.
The Toll-like receptor 7 is highly expressed in monocytes, B lymphocytes and dendritic cells. Once foreign substance invasion is recognized, considerable quantities of type I interferon are produced, especially interferon-α, which plays an important role in innate immune response. The Toll-like receptor 7 detects G/U-rich ssRNA, which is derived from viruses, for example, human immunodeficiency virus (HIV) and VSV.
With the development of drugs, the Toll-like receptor 9 antagonist has entered clinical trials, which stimulates dendritic cells to produce IL-12 and considerable quantities of interferon-α and induces B lymphocyte proliferation and antibody secretion, with a good curative effect on HVC patients whom did not positively react to the conventional interferon- α treatment. Toll-like receptor 9 antagonist induces cells to exhibit a wide antiviral response and release various cytokines, especially interferon-α, achieving a high virus scavenging efficiency on various HVC genotype patients.
Currently, various antiviral drugs have been developed and widely applied in clinical therapy, for example, ribavirin, a nucloside analog, inhibiting growth of various viruses such as respiratory syncytial virus, influenza virus, adenovirs, HIV and HCV, amantadine, inhibiting M2 membrane proteins of influenza virus A to block virus replication, and zidovudine (AZT) , didanosine (ddl) , zalcitabine (ddc) , stavudine (d4T) and lamivudine
(3TC), inhibiting reverse transcriptase of HIV to block reverse transcription from RNA to DNA so as to break DNA synthesis.
Although many antiviral drugs have been effectively utilized in clinical therapy, the problem of drug resistance gradually occurs, due to virus gene mutation such that binding targets for antiviral drugs disappear. For example, mutation of the thymidine kinase gene of the HSV results in blocking of the conversion from acyclovir and ganciclovir to effective substances in cells, thus forming drug resistance to such drugs. Additionally, mutation of the M2 membrane protein gene of influenza virus A results in formation of drug resistance to amantadine and rimantadine, mutation of the reverse transcriptase or protease gene of HIV results in formation of drug resistance, and mutation of the non- structural 5 A, envelope gene and 2-glycoprotein gene of HCV results in formation of drug resistance to interferon. Currently, more and more drug research have focused on immunomodulatory treatments. A foreign microorganism is scavenged by stimulating an innate immune response and adaptive immune response of host cells. Herbs have an advantage in immunomodulatory treatment, because they have no deteriorating effect on normal organisms but an improved effect (over other conventional methods) on immune-disordered organisms, wherein an abnormal immune state can be corrected for recovery and immune stability is retained.
Additionally, immunity of normal organisms may be simultaneously improved.
After thousands of years of consideration, herbs, possessing a natural structure and activity, have been proven to be a drug with determined curative effect.
In clinical trials, herbs exhibited prominent curative effects on viral diseases with various pathogenicity, latency periods and infection routes, for example, for viral diseases such as hepatitis B, hepatitis C, influenza, epidemic parotitis, epidemic cerebrospinal meningitis, viral hepatitis, enterovirus and AIDS. US. Pat. 6,787,165 discloses a composition comprising a supercritical extract of Flos Lonicerae and Fructus Forsythiae, an aqueous extract of Flos Lonicerae and Fructus Forsythiae, and an aqueous extract of Scutellariae Radix, which inhibited the influenza virus. US. Pat. 6,696,094 discloses a pharmaceutical composition containing aqueous extracts of fourteen (14) herbal ingredients including Hedyotis Diffuse and so on, with the form of an intravenous injection solution or capsules, exhibiting an anti-HIV effect in clinical trials. US. Pat. 6,214,350 discloses an herbal prescription (HHT888-4) containing Flos Lonicerae, Glycyrrhizae Radix and Solarium Nigrum, which inhibited HIV activity to achieve over 98% in lymphocytes in vitro trials. US. Pat. 6,426,098 discloses an herbal extract comprising Curcuma Longa, Astragalus Membranaceus, Loranthus Parasiticus and Polygonum Cuspidatum, which possessed a prominent curative effect on hepatitis C in clinical trials.
Additionally, utilization of herbs have been incorporated in western medicine treatments. US. Pat. 2003/0211180 discloses an herbal composition (PHY906) comprising Ziziphus, which is utilized with chemotherapy drugs to increase curative effects on viral diseases, improve quality of life and reduce toxicity and negative side effects. The herbal composition has already entered the phase-II clinical trials in the U.S.. Taiwan Pat. 1258373 discloses utilization of a hepatitis C assisted drug comprising Cordyceps Sinensis and Astragalus Membranaceus, which is incorporated with a hepatitis C composite treatment (interferon and ribavirin) to achieve over 70% virus scavenging efficiency. In addition to curative effect, recurrence is reduced.
Induction of interferon is significant for viral hepatitis treatments. WO 02102395 discloses an antiviral effect of an herbal extract comprising Nerium Indicum Mill and Glycyrrhizae Radix on HEp-2 cells infected by encephalo-myocarditis virus (EMCV). EMCV is effectively inhibited. In vitro, interferon-γ is also produced thereby. There are ten Toll-like receptors (TLRs) in the human immune system. When suffering from the threat of pathogens (virus, bacteria or fungus), individual TLRs recognize pathogens and start corresponding immune responses. Binding between TLRs and pathogens are specific, inducing a series of reactions to protect cells from pathogen invasion. In TLR treatment, due to a high specificity of TLR to immune response, stimulators (agonists) or blockers (antagonists) are specifically administrated to induce self-immunomodulatory to achieve curative effect. Due to the high specificity of the treatment, in addition to continuous inhibition of pathogens, side effects and disorders resulting from non-specific activation of the innate immune system are reduced.
Actilon (a TLR drug), a synthetic short-chain oligonucleotides (ODNs) compound, has been developed by the Coley Pharmaceutical Group. The short-chain ODNs compound is similar to the DNA sequence, with a CpG structure of pathogen recognizable by TLR-9. After presentation of TLR-9 and a series of signal transduction pathway, interferon is produced to treat a viral disease, for example, hepatitis C. Actilon has entered phase-Ib clinical trials. Additionally, ANA245 and ANA975 (oral form) developed by Anadys Pharmaceutical Corporation is utilized to induce TLR-7 presentation. They have respectively entered phase-Ib and phase-la clinical trials. Also, herbal extracts can be utilized in TLR treatments. WO 04093518 discloses a melanin extract oi Echinacea, which was tested in monocyte (NF-kappa B/luciferase) in vitro. The melanin extract induced presentation of TLR-2 and TLR-4.
BRIEF SUMMARY OF THE INVENTION
One embodiment of the invention provides an herbal extract which induces immune cells to produce interferon and activates Toll-like receptors, extracted from an effective amount of raw material comprising Glycyrrhizae Radix, Bupleuri Radix and Scutellariae Radix, wherein
Glycyrrhizae Radix, Bupleuri Radix and Scutellariae Radix have a weight ratio of 1-5: 1-5: 1-5 or 1-2: 1-2: 1-2.
Glycyrrhizae Radix comprises Glycyrrhiza uralensis or Glycyrrhiza glabra. Bupleuri Radix comprises Bupleurum chinense or Bupleurum scorzonerifolium. Scutellariae Radix comprises Scutellaria baicalensis.
In an embodiment, the raw material of the herbal extract further comprises an effective amount of Schisandrae Fructus and Paeoniae Rubra Radix. Glycyrrhizae Radix, Bupleuri Radix, Scutellariae Radix, Schisandrae Fructus and Paeoniae Rubra Radix have a weight ratio of 1-5: 1-5: 1-5: 1-3: 1-3 or 1-2: 1-2: 1-2: 1-2: 1-2. Schisandrae Fructus comprises Schisandra chinensis or Schisandra sphenanthera. Paeoniae Rubra Radix comprises Paeonia lacti flora or Paeonia veitchii.
The herbal extract activates various Toll-like receptors, for example, Toll-like receptor 2, Toll-like receptor 4 and Toll-like receptor 7. The herbal extract strengthens immune regulation, suitable for use in treatment of viral infectious diseases. One embodiment of the invention provides a method for preparing an herbal extract which induces immune cells to produce interferon and activates Toll-like receptors, comprising providing an herbal composition comprising an effective amount of Glycyrrhizae Radix, Bupleuri Radix and Scutellariae Radix, wherein Glycyrrhizae Radix, Bupleuri Radix and Scutellariae Radix have a weight ratio of 1-5: 1-5: 1-5 or 1-2: 1-2: 1-2, extracting the herbal composition with a solvent to form an extract solution, concentrating the extract solution to form a concentrated product, drying the concentrated product and adding an excipient to prepare a specific formulation.
Glycyrrhizae Radix comprises Glycyrrhiza uralensis or Glycyrrhiza glabra. Bupleuri Radix comprises Bupleurum chinense or Bupleurum scorzonerifolium. Scutellariae Radix comprises Scutellaria baicalensis.
In an embodiment, the herbal composition further comprises an effective amount of Schisandrae Fructus and Paeoniae Rubra Radix. Glycyrrhizae Radix, Bupleuri Radix, Scutellariae Radix, Schisandrae Fructus and Paeoniae Rubra Radix have a weight ratio of 1- 5: 1-5: 1-5: 1-3:1-3 or 1-2: 1-2: 1-2: 1-2: 1-2. Schisandrae Fructus comprises Schisandra chinensis or Schisandra sphenanthera. Paeoniae Rubra Radix comprises Paeonia lactiflora or Paeonia veitchii.
The solvent comprises water or 0.1-95% ethanol. The solvent and the herbal composition have a weight ratio of 6: 1-10: 1. The concentrated product has a solid content of 10-30%. The concentrated product is dried by vacuum drying, freeze drying, spray drying or fluidized bed drying. The excipient comprises starch, maltose, lactose, sucrose, mannitol, magnesium stearate, silicon dioxide, microcrystalline cellulose, carboxymethyl cellulose or talc powder. The specific formulation comprises capsule, tablet, powder or fluid.
A detailed description is given in the following embodiments with reference to the accompanying drawings.
BRIEF DESCRIPTION OF THE DRAWINGS
The invention can be more fully understood by reading the subsequent detailed description and examples with references made to the accompanying drawing, wherein:
FIG. IA shows cell toxicity of the herbal extract in neutrophil according to an embodiment of the invention.
FIG. IB shows cell toxicity of the herbal extract in T lymphocytes according to an embodiment of the invention.
FIG. 2A shows quantity of interferon-γ produced by inducing natural killer cells and T lymphocytes by the herbal extract according to an embodiment of the invention.
FIG. 2B shows quantity of interferon-α produced by inducing natural killer cells by the herbal extract according to an embodiment of the invention.
FIG. 2C shows quantity of interferon-α produced by inducing T lymphocytes by the herbal extract according to an embodiment of the invention.
FIG. 3 shows quantity of interferon-γ induced by the herbal extract in a subject according to an embodiment of the invention. FIGS. 4A-4I show expressions of Toll-like receptors of PBMC/T cells activated by the herbal extract according to an embodiment of the invention.
FIGS. 5A-5I show expressions of Toll-like receptors of PBMC/T cells activated by the herbal extract according to an embodiment of the invention.
FIGS. 6A-6I show expressions of Toll-like receptors of PBMC/T cells activated by the herbal extract according to an embodiment of the invention.
FIGS. 7A-7I show expressions of Toll-like receptors of PBMC/T cells activated by the herbal extract according to an embodiment of the invention.
FIGS. 8A-8I show expressions of Toll-like receptors of PBMC/T cells activated by the herbal extract according to an embodiment of the invention. FIGS. 9A-9I show expressions of Toll-like receptors of PBMC/T cells activated by the herbal extract according to an embodiment of the invention.
FIGS. 10A- 101 show expressions of Toll-like receptors of PBMC/T cells activated by the herbal extract according to an embodiment of the invention.
FIGS. 1 IA-I II show expressions of Toll-like receptors of PBMC/T cells activated by the herbal extract according to an embodiment of the invention.
DETAILED DESCRIPTION OF THE INVENTION
The following description is of the best-contemplated mode of carrying out the invention. This description is made for the purpose of illustrating the general principles of the invention and should not be taken in a limiting sense. The scope of the invention is best determined by reference to the appended claims.
One embodiment of the invention provides an herbal extract which induces immune cells to produce interferon and activates Toll-like receptors, extracted from an effective amount of raw material comprising Glycyrrhizae Radix, Bupleuri Radix and Scutellariae Radix.
Glycyrrhizae Radix, Bupleuri Radix and Scutellariae Radix have a weight ratio of about 1-5: 1-5: 1-5 or 1-2: 1-2: 1-2. Glycyrrhizae Radix may comprise Glycyrrhiza uralensis or Glycyrrhiza glabra.
Bupleuri Radix may comprise Bupleurum chinense or Bupleurum scorzonerifolium.
Scutellariae Radix may comprise Scutellaria baicalensis.
In an embodiment, the raw material of the herbal extract may further comprise an effective amount of Schisandrae Fructus and Paeoniae Rubra Radix. Glycyrrhizae Radix, Bupleuri Radix, Scutellariae Radix, Schisandrae Fructus and Paeoniae Rubra Radix have a weight ratio of about 1-5: 1-5: 1-5: 1-3: 1-3 or 1-2:1-2: 1-2: 1-2: 1-2. Schisandrae Fructus may comprise Schisandra chinensis or Schisandra sphenanthera. Paeoniae Rubra Radix may comprise Paeonia lactiflora or Paeonia veitchii.
The herbal extract activates various Toll-like receptors, for example, Toll-like receptor 2, Toll-like receptor 4 and Toll-like receptor 7.
One embodiment of the invention provides a method for preparing an herbal extract which induces immune cells to produce interferon and activates Toll-like receptors, comprising the following steps. An herbal composition comprising an effective amount of Glycyrrhizae Radix, Bupleuri Radix and Scutellariae Radix is provided. Glycyrrhizae Radix, Bupleuri Radix and Scutellariae Radix have a weight ratio of about 1-5: 1-5: 1-5 or 1-2: 1-2: 1-2. The herbal composition is then extracted with a solvent to form an extract solution. Next, the extract solution is concentrated to form a concentrated product. The concentrated product is then dried. Next, an excipient is added to prepare a specific formulation.
Glycyrrhizae Radix may comprise Glycyrrhiza uralensis or Glycyrrhiza glabra. Bupleuri Radix may comprise Bupleurum chinense or Bupleurum scorzonerifolium.
Scutellariae Radix may comprise Scutellaria baicalensis.
In an embodiment, the herbal composition may further comprise an effective amount of Schisandrae Fructus and Paeoniae Rubra Radix. Glycyrrhizae Radix, Bupleuri Radix, Scutellariae Radix, Schisandrae Fructus and Paeoniae Rubra Radix have a weight ratio of about 1-5: 1-5: 1-5: 1-3: 1-3 or 1-2: 1-2: 1-2: 1-2: 1-2. Schisandrae Fructus may comprise Schisandra chinensis or Schisandra sphenanthera. Paeoniae Rubra Radix may comprise Paeonia lactiflora or Paeonia veitchii. The solvent may comprise water or 0.1-95% ethanol. The solvent and the herbal composition have a weight ratio of about 6: 1-10: 1. The concentrated product has a solid content of about 10-30%. The concentrated product is dried by, for example, vacuum drying, freeze drying, spray drying or fluidized bed drying. The excipient may comprise starch, maltose, lactose, sucrose, mannitol, magnesium stearate, silicon dioxide, microcrystalline cellulose, carboxymethyl cellulose or talc powder. The specific formulation may comprise capsule, tablet, powder or fluid.
A raw material comprising Glycyrrhizae Radix, Bupleuri Radix, Scutellariae Radix,
Schisandrae Fructus and Paeoniae Rubra Radix with a specific weight ratio is provided. The raw material is then extracted with 0.1-95% ethanol one or more times to form an extract solution. The weight of the ethanol is 6-fold to 10-fold times the raw material. Next, the extract solution is concentrated to form a concentrated product with a solid content of 10-30%.
An excipient is then added and the product was freeze-dried to form a dried product with a water content of 2-10%. Next, the dried product is grounded to form powders with a diameter of less than 35mesh. The dried herbal extract powders are then filled in a hard capsule. Each capsule is filled with about 1.35±0.09g of the herbal extracts. The herbal extract is concentrated to 2-fold to 3 -fold times the original content.
In the invention, interferon production and Toll-like receptor expression, for example, Toll-like receptor 2, Toll-like receptor 4 and Toll-like receptor 7 expressions, in neutrophil, T lymphocytes and natural killer cells are observed. The results act as a drug screening basis.
Herbal extract preparation
Example 1
A solution containing 4kg Scutellaria baicalensis, 4kg Bupleurum chinense, 4kg
Glycyrrhiza uralensis, 4kg Paeonia lactiflora, 4kg Schisandra chinensis (a weight ratio of 1 : 1 : 1 : 1 : 1) and 200kg ethanol (30%) was thermal-extracted with reflux for one hour. After two extractions, an extract solution was formed and filtered through a lOOmesh. After reduced pressure concentration, a concentrated product with a 15% solid content was formed. 2kg dextrin-maltose was then added and the product was freeze-dried to form a dried product. Next, the dried product was grounded to form powders with a diameter of less than 35mesh and then the product was blended with 12Og silicon dioxide and 6Og magnesium stearate. The dried herbal extract powders were then filled in a 0# hard capsule. The filling amount of each capsule was 565±40mg, approximately 1.35±0.09g of herbal extracts. Example 2
A solution containing 2.5g Scutellaria baicalensis, 2.5g Bupleurum chinense, 2.5g
Glycyrrhiza uralensis, 7.5g Paeonia lacti flora, 7.5g Schisandra chinensis (a weight ratio of 1 : 1 : 1 :3:3) and 25Og ethanol (30%) was thermal-extracted with reflux for one hour. After two extractions, an extract solution was formed and filtered through a lOOmesh. After reduced pressure concentration and freeze-drying, a dried product was grounded to form powders.
Example 3
A solution containing 12.5g Scutellaria baicalensis, 6.25g Bupleurum chinense, 6.25g
Glycyrrhiza uralensis (a weight ratio of 2: 1 : 1) and 25Og ethanol (30%) was thermal-extracted with reflux for one hour. After two extractions, an extract solution was formed and filtered through a lOOmesh. After reduced pressure concentration and freeze-drying, a dried product was grounded to form powders.
Example 4
A solution containing 6.25g Scutellaria baicalensis, 12.5g Bupleurum chinense, 6.25g Glycyrrhiza uralensis (a weight ratio of 1 :2: 1) and 25Og ethanol (30%) was thermal-extracted with reflux for one hour. After two extractions, an extract solution was formed and filtered through a lOOmesh. After reduced pressure concentration and freeze-drying, a dried product was grounded to form powders. Example 5 A solution containing 6.25g Scutellaria baicalensis, 6.25g Bupleurum chinense, 12.5g
Glycyrrhiza uralensis (a weight ratio of 1 : 1 :2) and 25Og ethanol (30%) was thermal-extracted with reflux for one hour. After two extractions, an extract solution was formed and filtered through a lOOmesh. After reduced pressure concentration and freeze-drying, a dried product was grounded to form powders. Example 6
A solution containing 5g Scutellaria baicalensis, 5g Bupleurum chinense, 5g Glycyrrhiza uralensis, 5g Paeonia lactiflora, 5g Schisandra chinensis (a weight ratio of 1 : 1 : 1 : 1 : 1) and 25Og water was thermal-extracted with reflux for one hour. After two extractions, an extract solution was formed and filtered through a lOOmesh. After reduced pressure concentration and freeze-drying, a dried product was grounded to form powders.
Example 7
A solution containing 5g Scutellaria baicalensis, 5g Bupleurum chinense, 5g Glycyrrhiza uralensis, 5g Paeonia lactiflora, 5g Schisandra chinensis (a weight ratio of 1 : 1 : 1 : 1 : 1) and 25Og ethanol (50%) was thermal-extracted with reflux for one hour. After two extractions, an extract solution was formed and filtered through a lOOmesh. After reduced pressure concentration and freeze-drying, a dried product was grounded to form powders. Example 8
A solution containing 5g Scutellaria baicalensis, 5g Bupleurum chinense, 5g Glycyrrhiza uralensis, 5g Paeonia lactiflora, 5g Schisandra chinensis (a weight ratio of 1 : 1 : 1 : 1 : 1) and 25Og ethanol (95%) was thermal-extracted with reflux for one hour. After two extractions, an extract solution was formed and filtered through a lOOmesh. After reduced pressure concentration and freeze-drying, a dried product was grounded to form powders.
Cell toxicity of herbal extract in neutrophil and T lymphocytes
Example 9
Cells were cultured in a 96-well plate. The herbal extract (prepared by Example 1) was then added. Next, lOμL Alamarblue dye was added and placed in a culture box at 370C for 16 hours. The absorption values at 570nm and 600nm were measured, and are shown in FIGS.
IA and IB. The results indicated that the cell toxicity of the herbal extract in neutrophil and
T lymphocytes is non-obvious.
Test of inducing immune cells to produce interferon by an herbal extract
Example 10 The herbal extract (prepared by Example 1) was added in T lymphocytes and natural killer cells (NK92) separated from peripheral blood. After 24 hours, the upper-layered solution was collected and the quantity of interferon thereof was measured by ELISA. The results indicated that the quantity of interferon-γ increased as the concentration of the herbal extract increased, exhibiting a dosage effect, as shown in FIG. 2A. The dosage effect appears in both the T lymphocytes and natural killer cells (NK92). The quantity of interferon-α induced by PC-IL- 12 (positive control) and the herbal extract was measured in the same manner. The results indicated that the quantity of interferon-α produced by inducing natural killer cells (NK92) by the herbal extract with lOOμg/mL is more than that produced by inducing natural killer cells (NK92) by the herbal extract with other concentrations. Additionally, the quantity of interferon-α produced by inducing T lymphocytes by the herbal extract with 250-l,000μg/mL was obvious, as shown in FIGS. 2B and 2C. Example 11 The inducing activity for interferon-γ of the herbal extract (prepared by Example 3) was tested. The results indicated that the immune cells were induced by the sample with 500μg/mL to produce interferon-γ of 94.3+15.7pg/mL (the immune cells were induced by IL- 12 (positive control) with 40ng/mL to produce interferon-γ of 50+2.04pg/mL). Example 12
The inducing activity for interferon-γ of the herbal extract (prepared by Example 5) was tested. The results indicated that the immune cells were induced by the sample with 500μg/mL to produce interferon-γ of 129.1+8.5pg/mL (the immune cells were induced by IL- 12 (positive control) with 40ng/mL to produce interferon-γ of 50+2.04pg/mL). Example 13
The inducing activity for interferon-γ of the herbal extract (prepared by Example 6) was tested. The results indicated that the immune cells were induced by the sample with l,000μg/mL to produce interferon-γ of 95.2+15.7pg/mL (the immune cells were induced by IL-12 (positive control) with 40ng/mL to produce interferon-γ of 50+2.04pg/mL). Example 14
The inducing activity for interferon-γ of the herbal extract (prepared by Example 7) was tested. The results indicated that the immune cells were induced by the sample with l,000μg/mL to produce interferon-γ of l,563.6+44.9pg/mL (the immune cells were induced by IL-12 (positive control) with 40ng/mL to produce interferon-γ of 50+2.04pg/mL). Example 15
The inducing activity for interferon-γ of the herbal extract (prepared by Example 8) was tested. The results indicated that the immune cells were induced by the sample with 500μg/mL to produce interferon-γ of 80.2+24.6pg/mL (the immune cells were induced by IL- 12 (positive control) with 40ng/mL to produce interferon-γ of 50+2.04pg/mL). Test of inducing rates to produce interferon by the herbal extract
Example 16
The inducing activity for interferon-γ in a living animal of the herbal extract (prepared by Example 1) was tested. After feeding (28 days), the quantity of interferon-γ in blood of Wistar rats (control: drinking water; medium: feeding the herbal extract of 5g/kg; high: feeding the herbal extract of 10g/kg) was measured on the 29th day. The results indicated that the quantity of interferon-γ induced by the herbal extract in a subject was obvious, especially in female rats, as shown in FIG. 3. Test of expression of Toll-like receptors of PBMC/T cells activated by the herbal extract
Example 17
The expressions of Toll-like receptor 2 (TLR2), Toll-like receptor 4 (TLR4) and Toll- like receptor 7 (TLR7) activated by the herbal extract (prepared by Example 1) were tested. The cells were labeled by dyeing with TLR2, TLR4 and TLR7 antibodies and then analyzed by a fluorescence activated cell sorter (FACS). The results indicated that when a low dosage (250μg/mL) of the herbal extract was applied, expressions of above 75% for the TLR2, TLR4 or TLR7 were achieved , as shown in FIGS. 4A-4I.
Example 18 The expressions of Toll-like receptor 2 (TLR2), Toll-like receptor 4 (TLR4) and Toll- like receptor 7 (TLR7) activated by the herbal extract (prepared by Example 2) were tested. The results are shown in FIGS. 5A-5I. When the herbal extract of 500μg/mL was applied, expressions of above 65% for the TLR2, TLR4 and TLR7 were achieved.
Example 19 The expressions of Toll-like receptor 2 (TLR2), Toll-like receptor 4 (TLR4) and Toll- like receptor 7 (TLR7) activated by the herbal extract (prepared by Example 3) were tested. The results are shown in FIGS. 6A-6I. When a low dosage (250μg/mL) of the herbal extract was applied, expressions of above 60% for the TLR2, TLR4 and TLR7 were achieved.
Example 20 The expressions of Toll-like receptor 2 (TLR2), Toll-like receptor 4 (TLR4) and Toll- like receptor 7 (TLR7) activated by the herbal extract (prepared by Example 4) were tested. The results are shown in FIGS. Ik-Il. When a low dosage (250μg/mL) of the herbal extract was applied, expressions of above 85% for theTLR2, TLR4 and TLR7 were achieved.
Example 21 The expressions of Toll-like receptor 2 (TLR2), Toll-like receptor 4 (TLR4) and Toll- like receptor 7 (TLR7) activated by the herbal extract (prepared by Example 5) were tested. The results are shown in FIGS. 8A-8I. When a low dosage (250μg/mL) of the herbal extract was applied, expressions of above 80% for the TLR2, TLR4 and TLR7 were achieved. Example 22 The expressions of Toll-like receptor 2 (TLR2), Toll-like receptor 4 (TLR4) and Toll- like receptor 7 (TLR7) activated by the herbal extract (prepared by Example 6) were tested. The results are shown in FIGS. 9A-9I. When a low dosage (250μg/mL) of the herbal extract was applied, expressions of above 85% for the TLR2, TLR4 and TLR7 were achieved.
Example 23
The expressions of Toll-like receptor 2 (TLR2), Toll-like receptor 4 (TLR4) and Toll- like receptor 7 (TLR7) activated by the herbal extract (prepared by Example 7) were tested. The results are shown in FIGS. 10A-10I. When a low dosage (250μg/mL) of the herbal extract was applied, expressions of above 94% for the TLR2, TLR4 and TLR7 were achieved.
Example 24
The expressions of Toll-like receptor 2 (TLR2), Toll-like receptor 4 (TLR4) and Toll- like receptor 7 (TLR7) activated by the herbal extract (prepared by Example 8) were tested. The results are shown in FIGS. 1 IA-I II. When a low dosage (250μg/mL) of the herbal extract was applied, expressions of above 75% for the TLR2, TLR4 and TLR7 were achieved.
While the invention has been described by way of example and in terms of the preferred embodiment, it is to be understood that the invention is not limited thereto. To the contrary, it is intended to cover various modifications and similar arrangements (as would be apparent to those skilled in the art). Therefore, the scope of the appended claims should be accorded the broadest interpretation so as to encompass all such modifications and similar arrangements.

Claims

1. An herbal extract which induces immune cells to produce interferon, extracted from an effective amount of raw material comprising Glycyrrhizae Radix, Bupleuri Radix and Scutellariae Radix, wherein Glycyrrhizae Radix, Bupleuri Radix and Scutellariae Radix have a weight ratio of 1-5: 1-5: 1-5.
2. The herbal extract which induces immune cells to produce interferon as claimed in claim 1, wherein Glycyrrhizae Radix, Bupleuri Radix and Scutellariae Radix have a weight ratio of 1-2: 1-2: 1-2.
3. The herbal extract which induces immune cells to produce interferon as claimed in claim 1, wherein the raw material further comprises an effective amount of
Schisandrae Fructus and Paeoniae Rubra Radix.
4. The herbal extract which induces immune cells to produce interferon as claimed in claim 3, wherein Glycyrrhizae Radix, Bupleuri Radix, Scutellariae Radix, Schisandrae Fructus and Paeoniae Rubra Radix have a weight ratio of 1-5: 1-5: 1-5: 1- 3: 1-3.
5. The herbal extract which induces immune cells to produce interferon as claimed in claim 4, wherein Glycyrrhizae Radix, Bupleuri Radix, Scutellariae Radix, Schisandrae Fructus and Paeoniae Rubra Radix have a weight ratio of 1-2: 1-2: 1-2: 1- 2: 1-2.
6. A method for preparing an herbal extract which induces immune cells to produce interferon, comprising: providing an herbal composition comprising an effective amount of Glycyrrhizae Radix, Bupleuri Radix and Scutellariae Radix, wherein Glycyrrhizae Radix, Bupleuri Radix and Scutellariae Radix have a weight ratio of 1-5: 1-5: 1-5; extracting the herbal composition with a solvent to form an extract solution; concentrating the extract solution to form a concentrated product; drying the concentrated product; and adding an excipient to prepare a specific formulation.
7. The method for preparing an herbal extract which induces immune cells to produce interferon as claimed in claim 6, wherein the herbal composition further comprises an effective amount of Schisandrae Fructus and Paeoniae Rubra Radix.
8. The method for preparing an herbal extract which induces immune cells to produce interferon as claimed in claim 7, wherein Glycyrrhizae Radix, Bupleuri
Radix, Scutellariae Radix, Schisandrae Fructus and Paeoniae Rubra Radix have a weight ratio of 1-5: 1-5: 1-5: 1-3: 1-3.
9. The method for preparing an herbal extract which induces immune cells to produce interferon as claimed in claim 8, wherein Glycyrrhizae Radix, Bupleuri Radix, Scutellariae Radix, Schisandrae Fructus and Paeoniae Rubra Radix have a weight ratio of 1-2: 1-2: 1-2: 1-2: 1-2.
10. The method for preparing an herbal extract which induces immune cells to produce interferon as claimed in claim 6, wherein the solvent comprises water or 0.1-95% ethanol.
11. The method for preparing an herbal extract which induces immune cells to produce interferon as claimed in claim 6, wherein the solvent and the herbal composition have a weight ratio of 6: 1-10: 1.
12. The method for preparing an herbal extract which induces immune cells to produce interferon as claimed in claim 6, wherein the concentrated product has a solid content of 10-30%.
13. The method for preparing an herbal extract which induces immune cells to produce interferon as claimed in claim 6, wherein the concentrated product is dried by vacuum drying, freeze drying, spray drying or fluidized bed drying.
14. The method for preparing an herbal extract which induces immune cells to produce interferon as claimed in claim 6, wherein the excipient comprises starch, maltose, lactose, sucrose, mannitol, magnesium stearate, silicon dioxide, microcrystalline cellulose, carboxymethyl cellulose or talc powder.
15. The method for preparing an herbal extract which induces immune cells to produce interferon as claimed in claim 6, wherein the specific formulation comprises capsule, tablet, powder or fluid.
16. An herbal extract which activates Toll-like receptors, extracted from an effective amount of raw material comprising Glycyrrhizae Radix, Bupleuri Radix and Scutellariae Radix, wherein Glycyrrhizae Radix, Bupleuri Radix and Scutellariae Radix have a weight ratio of 1-5: 1-5: 1-5.
17. The herbal extract which activates Toll-like receptors as claimed in claim 16, wherein the herbal extract activates Toll-like receptor 2, Toll-like receptor 4 and Toll-like receptor 7.
18. The herbal extract which activates Toll-like receptors as claimed in claim 16, wherein Glycyrrhizae Radix, Bupleuri Radix and Scutellariae Radix have a weight ratio of 1 -2 : 1 -2 : 1 -2 .
19. The herbal extract which activates Toll-like receptors as claimed in claim 16, wherein the raw material further comprises an effective amount of Schisandrae Fructus and Paeoniae Rubra Radix.
20. The herbal extract which activates Toll-like receptors as claimed in claim 19, wherein Glycyrrhizae Radix, Bupleuri Radix, Scutellariae Radix, Schisandrae Fructus and Paeoniae Rubra Radix have a weight ratio of 1-5: 1-5: 1-5: 1-
3: 1-3.
21. The herbal extract which activates Toll-like receptors as claimed in claim 20, wherein Glycyrrhizae Radix, Bupleuri Radix, Scutellariae Radix, Schisandrae Fructus and Paeoniae Rubra Radix have a weight ratio of 1-2: 1-2: 1-2: 1- 2: 1-2.
22. A method for preparing an herbal extract which activates Toll-like receptors, comprising: providing an herbal composition comprising an effective amount of Glycyrrhizae Radix, Bupleuri Radix and Scutellariae Radix, wherein Glycyrrhizae Radix, Bupleuri Radix and Scutellariae Radix have a weight ratio of 1-5: 1-5: 1-5; extracting the herbal composition with a solvent to form an extract solution; concentrating the extract solution to form a concentrated product; drying the concentrated product; and adding an excipient to prepare a specific formulation.
23. The method for preparing an herbal extract which activates Toll-like receptors as claimed in claim 22, wherein the herbal composition further comprises an effective amount of Schisandrae Fructus and Paeoniae Rubra Radix.
24. The method for preparing an herbal extract which activates Toll-like receptors as claimed in claim 23, wherein Glycyrrhizae Radix, Bupleuri Radix, Scutellariae Radix, Schisandrae Fructus and Paeoniae Rubra Radix have a weight ratio of 1-5: 1-5: 1-5: 1-3: 1-3.
25. The method for preparing an herbal extract which activates Toll-like receptors as claimed in claim 24, wherein Glycyrrhizae Radix, Bupleuri Radix, Scutellariae Radix, Schisandrae Fructus and Paeoniae Rubra Radix have a weight ratio of 1-2: 1-2: 1-2: 1-2: 1-2.
26. The method for preparing an herbal extract which activates Toll-like receptors as claimed in claim 22, wherein the solvent comprises water or 0.1-95% ethanol.
27. The method for preparing an herbal extract which activates Toll-like receptors as claimed in claim 22, wherein the solvent and the herbal composition have a weight ratio of 6: 1-10: 1.
28. The method for preparing an herbal extract which activates Toll-like receptors as claimed in claim 22, wherein the concentrated product has a solid content of 10-30%.
29. The method for preparing an herbal extract which activates Toll-like receptors as claimed in claim 22, wherein the concentrated product is dried by vacuum drying, freeze drying, spray drying or fluidized bed drying.
30. The method for preparing an herbal extract which activates Toll-like receptors as claimed in claim 22, wherein the excipient comprises starch, maltose, lactose, sucrose, mannitol, magnesium stearate, silicon dioxide, microcrystalline cellulose, carboxymethyl cellulose or talc powder.
31. The method for preparing an herbal extract which activates Toll-like receptors as claimed in claim 22, wherein the specific formulation comprises capsule, tablet, powder or fluid.
PCT/CN2009/070570 2008-05-30 2009-02-27 Herbal extracts which induce immune cells to produce interferon and activate toll-like receptors WO2009143719A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2008100987126A CN101590105B (en) 2008-05-30 2008-05-30 Chinese medicinal herb extract for inducing immune cells to generate interferon and activated TOLL-like receptors and preparation method thereof
CN200810098712.6 2008-05-30
US12/164,958 2008-06-30
US12/164,958 US20090280200A1 (en) 2008-05-08 2008-06-30 Herbal extracts which induce immune cells to produce interferon and activate toll-like receptors

Publications (1)

Publication Number Publication Date
WO2009143719A1 true WO2009143719A1 (en) 2009-12-03

Family

ID=41376582

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2009/070570 WO2009143719A1 (en) 2008-05-30 2009-02-27 Herbal extracts which induce immune cells to produce interferon and activate toll-like receptors

Country Status (2)

Country Link
CN (1) CN101590105B (en)
WO (1) WO2009143719A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2971116A4 (en) * 2013-03-15 2016-12-14 Broad Inst Inc Dendritic cell response gene expression, compositions of matters and methods of use thereof
CN114164304A (en) * 2021-12-28 2022-03-11 天津瑞普生物技术股份有限公司 Method for detecting activity of cat interferon

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI610679B (en) * 2016-11-30 2018-01-11 財團法人工業技術研究院 Use of an ethanol extract of chinese herb and a pharmaceutical composition containing the ethanol extract of chinese herb and a steroid

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1562229A (en) * 2004-03-18 2005-01-12 陈绍先 Formula of Chinese herbal medicine decoction distinguished from males and females and combined with Western medicine for curing hepatitis B
CN101088555A (en) * 2007-06-04 2007-12-19 陈大刚 Medicine prepn for inhibiting tumor angiogenesis and cancer cell and enhancing immunity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1060938C (en) * 1993-03-18 2001-01-24 李成兴 Chinese medicinal instant powder for treatment of B-hepatitis
CN1726960A (en) * 2004-07-27 2006-02-01 南京宇道科技开发有限公司 Combination of effective parts for curing chronic hepatitis, preparation and usage

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1562229A (en) * 2004-03-18 2005-01-12 陈绍先 Formula of Chinese herbal medicine decoction distinguished from males and females and combined with Western medicine for curing hepatitis B
CN101088555A (en) * 2007-06-04 2007-12-19 陈大刚 Medicine prepn for inhibiting tumor angiogenesis and cancer cell and enhancing immunity

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2971116A4 (en) * 2013-03-15 2016-12-14 Broad Inst Inc Dendritic cell response gene expression, compositions of matters and methods of use thereof
US10870885B2 (en) 2013-03-15 2020-12-22 The Broad Institute, Inc. Dendritic cell response gene expression, compositions of matters and methods of use thereof
CN114164304A (en) * 2021-12-28 2022-03-11 天津瑞普生物技术股份有限公司 Method for detecting activity of cat interferon

Also Published As

Publication number Publication date
CN101590105B (en) 2012-10-31
CN101590105A (en) 2009-12-02

Similar Documents

Publication Publication Date Title
US20090280200A1 (en) Herbal extracts which induce immune cells to produce interferon and activate toll-like receptors
Soufy et al. Antiviral and immune stimulant activities of glycyrrhizin against duck hepatitis virus
EP3295950B1 (en) Use of ginseng extract, ginsenoside and ginsenoside derivative in the preparation of medicine or health care product for treating cytomegalovirus infection disorders
Nagasaka et al. Efficacy of Kakkon‐to, a traditional herb medicine, in herpes simplex virus type 1 infection in mice
CN1872105A (en) Application of holly and extractive in preparing medication for anti virus
WO2009143719A1 (en) Herbal extracts which induce immune cells to produce interferon and activate toll-like receptors
CN103040989A (en) Antiviral Chinese traditional composition and preparation method thereof
US20030054047A1 (en) Pharmaceutical composition for the treatment of viral infection
CN105709206A (en) Medicine for treating fatty liver, hepatitis and liver cirrhosis
Kim et al. Inhibitory effect of emodin on raw 264.7 activated with double stranded rna analogue poly I: C
Song et al. Natural products: the master regulators of antiviral cytokines
KR20080092167A (en) Anti-hepatitis b virus agent from paeonia lactiflora
RU2643919C2 (en) Composition for prevention and treatment of aids and method of its production
CN101020027A (en) Medicine composition for preventing and treating AIDS and its prepn process and use
CN113318141B (en) Application of sand-induced grass extract
US20230338454A1 (en) Forsythia suspensa component and optional panax ginseng component and the application
CN102697800B (en) Herba stellariae mediae polysaccharide composition and the application in preparation antiviral drugs thereof
CN101502536B (en) Cedar total flavone as well as preparation method and medical use
KR102353942B1 (en) Drugs for alleviating or treating influenza virus infections, including Salicornia herbacea L.
KR20150027469A (en) Antiviral composition showing effects on NK cell activation
KR102497346B1 (en) Composition for enhancing immunity comprising exosome derived from antlers
CN102727850B (en) Medicinal composition for treating AIDS, a preparation method thereof, a quality control method and application thereof
Zhong et al. Modulation of antiviral cytokine production and lung protection against influenza virus by the glycosides from Ligustrum purpurascens
Kim et al. The Immunomodulating Effects of Aster Scaber $ T_ {HUNB} $ Extracts in Mice
Bellone et al. M. Ponticelli, ML Bellone, V. Parisi, AM Iannuzzi, A. Braca, N. De Tommasi, D. Russo, A. Sileo, P. Quaranta, G. Freer, M. Pistello

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09753437

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09753437

Country of ref document: EP

Kind code of ref document: A1